Abstract:Abstract Background Antiviral therapy has been shown to benefit long-term survival after curative hepatectomy in patients with hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) with high levels of HBV-DNA, but the impact of antiviral therapy on patient recurrence in patients with low levels of HBV-DNA remains less clear. Methods This was a retrospective cohort study analyzing 296 patients with HBV-associated HCC with HBV-DNA levels < 2000 IU/mL who underwent hepatectomy at Zhongnan Hospital of Wuhan University between March 2013 and December 2017, of whom 157 patients received antiviral therapy (antiviral group) and 139 patients did not receive antiviral therapy (non-antiviral group), propensity score matching was used for survival analysis of patients in both groups, and subgroup analysis of major risk factors was performed. Results The baseline characteristics of the two groups were comparable. At a median follow-up of 54 months, the 1-, 3-, and 5-year overall survival rates after propensity score matching (PSM) were 94.9%, 80.8%, 66.5%, and 90.9%, 64.6%, 49.4% for the antiviral and non-antiviral groups, respectively, p = 0.009, and the corresponding 1-, 3-, and 5-year RFS for the two groups were 81.8%, 76.8%, 76.8%, and 67.7%, 55.6%, 55.6%, respectively. p = 0.001, and the overall survival and recurrence-free survival were significantly better in the antiviral group than in the non-antiviral group. Multi-factor COX regression analysis showed that prothrombin time ≥ 13 s, methemoglobin level ≥ 20 ng/ml, platelet count ≥ 100 × 109/L, tumor size > 5 cm, tumor multiplicity was associated with early recurrence, and antiviral treatment was an independent protective factor for early recurrence of HCC (HR, 0.431; 95% CI 0.274–0.679; p < 0.001), but not associated with a low risk of late relapse (HR, 0.822; 95% CI 0.526–1.284; p = 0.389), and the main risk factors for late relapse included AST levels > 40 IU/ml, ALP levels > 130 IU/L, and the presence of satellite nodules, and subgroup analysis showed that compared to HBeAg-positive patients, antiviral therapy could significantly prolonged the recurrence-free survival of HBeAg-negative patients. Conclusion Antiviral therapy reduces early tumor recurrence after hepatectomy in patients with low levels of HBV-DNA.

Interferon‐α Therapy after Curative Resection Prevents Early Recurrence and Improves Survival in Patients with Hepatitis B Virus‐related Hepatocellular Carcinoma

Antiviral Therapy Improves Postoperative Survival of Patients with HBV-related Hepatocellular Carcinoma.

Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial.

Postoperative interferon α treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial

Interferon therapy improves survival in patients with hepatitis B virus-related hepatocellular carcinoma after curative surgery: a meta-analysis

Interferon Therapy after Curative Surgical Intervention to Improve Prognosis in Patients with Hepatitis C-related Hepatocellular Carcinoma: a Meta-analysis

Effects Of Interferon Alpha Treatment On Recurrence And Survival After Complete Resection Or Ablation Of Hepatocellular Carcinoma: A Meta-Analysis Of Randomized Controlled Trials

Combination therapy with transarterial chemoembolization and interferon-α compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma

Interferon Therapy after Tumor Ablation Improves Prognosis in Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus

Clinical Study on Radiofrequency Ablation,Sorafenib and Interferon-α for Recurrent Hepatocellular Carcinoma after Curative Resection

Antiviral Therapy Improves Postoperative Survival in Patients with Hepatocellular Carcinoma: a Randomized Controlled Trial.

Adjuvant Interferon for Early or Late Recurrence of Hepatocellular Carcinoma and Mortality from Hepatocellular Carcinoma Following Curative Treatment: A Meta-Analysis with Comparison of Different Types of Hepatitis.

A Comparative Study of Antiviral Therapy After Resection of Hepatocellular Carcinoma in the Immune-Active Phase of Hepatitis B Virus Infection

High-Dose and Long-Term Therapy with Interferon-Alfa Inhibits Tumor Growth and Recurrence in Nude Mice Bearing Human Hepatocellular Carcinoma Xenografts with High Metastatic Potential

Effect of antiviral therapy on survival of patients with intrahepatic recurrent after surgery for hepatitis B associated hepatocellular carcinoma

Antiviral Therapy Inhibits Viral Reactivation and Improves Survival after Repeat Hepatectomy for Hepatitis B Virus-Related Recurrent Hepatocellular Carcinoma

Early and Late Recurrence after Hepatectomy in Patients with Low-Level HBV-DNA Hepatocellular Carcinoma under Antiviral Therapy

The Effect of Antiviral Therapy on Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Curative Resection: a Systematic Review and Meta-Analysis

Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy.

Up-regulation of Platelet-Derived Growth Factor-a is Responsible for the Failure of Re-Initiated Interferon Alpha Treatment in Hepatocellular Carcinoma

Adjuvant Interferon Therapy for Hepatocellular Carcinoma after Curative Treatment:A Meta-Analysis of Randomized Controlled Trials